Article
作者: Zhu, Wei ; Jiang, Xiaotao ; He, Yajing ; Ma, Na ; Mo, Guoheng ; Li, Yongyin ; Zhang, Xiaoyong ; Li, Qi ; Huang, Lei ; Chen, Xiaolan ; Huang, Xuan ; Xu, Weikang ; Hou, Jinlin ; Lu, Xinyu ; Yi, Xuan ; Fu, Xin ; Wu, Sha ; Zang, Mengya ; He, Yukai ; Zhang, Zhiming ; Yuan, Guosheng ; Chen, Jinzhang ; Wang, Yiyue ; Li, Siwei
AbstractStrategies to improve T cell therapy efficacy in solid tumors such as hepatocellular carcinoma (HCC) are urgently needed. The common cytokine receptor γ chain (γc) family cytokines such as IL-2, IL-7, IL-15 and IL-21 play fundamental roles in T cell development, differentiation and effector phases. This study aims to determine the combination effects of IL-21 in T cell therapy against HCC and investigate optimized strategies to utilize the effect of IL-21 signal in T cell therapy. The antitumor function of AFP-specific T cell receptor-engineered T cells (TCR-T) was augmented by exogenous IL-21 in vitro and in vivo. IL-21 enhanced proliferation capacity, promoted memory differentiation, downregulated PD-1 expression and alleviated apoptosis in TCR-T after activation. A novel engineered IL-21 receptor was established, and TCR-T armed with the novel engineered IL-21 receptors (IL-21R-TCR-T) showed upregulated phosphorylated STAT3 expression without exogenous IL-21 ligand. IL-21R-TCR-T showed better proliferation upon activation and superior antitumor function in vitro and in vivo. IL-21R-TCR-T exhibited a less differentiated, exhausted and apoptotic phenotype than conventional TCR-T upon repetitive tumor antigen stimulation. The novel IL-21 receptor in our study programs powerful TCR-T and can avoid side effects induced by IL-21 systemic utilization. The novel IL-21 receptor creates new opportunities for next-generation TCR-T against HCC.